Evidence map›Paper›PMID 37315522›Full record

ArticleStem cell reports2023

Enrichment of stem cell-derived pancreatic beta-like cells and controlled graft size through pharmacological removal of proliferating cells.

Ali H Shilleh, Scott Beard, Holger A Russ

Open access · goldAbstract read
In one paragraph

Article in Stem cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ali H ShillehBarbara-Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Scott BeardBarbara-Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Holger A RussBarbara-Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Electronic address: holger.russ@ufl.edu.
University of Colorado Anschutz Medical Campus · US

Funding

University of Colorado Anschutz Medical Campus DRCP30DK116073 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI LORI SUSSEL · 2020 to 2026
$10.8M
Training in Translational Research of Skin DiseasesT32AR007411 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI ASGARI, MARYAM MANDANA, ROOP, DENNIS · 1986 to 2025
$4.8M
Improving human pluripotent stem cell derived beta cell transplantation using genetic lineage tracing.R01DK120444 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI RUSS, HOLGER A. · 2018 to 2021
$1.5M
Interdisciplinary Bioengineering Research Training in DiabetesT32DK120520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Richard KP Benninger, KATHRYN M HASKINS · 2020 to 2026
$1.1M
NIAMS NIH HHS T32 AR007411NIDDK NIH HHS P30 DK116073NIDDK NIH HHS R01 DK120444NIDDK NIH HHS T32 DK120520
6 · The paper itself

Abstract

Transplantation of limited human cadaveric islets into type 1 diabetic patients results in ∼35 months of insulin independence. Direct differentiation of stem cell-derived insulin-producing beta-like cells (sBCs) that can reverse diabetes in animal models effectively removes this shortage constraint, but uncontrolled graft growth remains a concern. Current protocols do not generate pure sBCs, but consist of only 20%-50% insulin-expressing cells with additional cell types present, some of which are proliferative. Here, we show the selective ablation of proliferative cells marked by SOX9 by simple pharmacological treatment in vitro. This treatment concomitantly enriches for sBCs by ∼1.7-fold. Treated sBC clusters show improved function in vitro and in vivo transplantation controls graft size. Overall, our study provides a convenient and effective approach to enrich for sBCs while minimizing the presence of unwanted proliferative cells and thus has important implications for current cell therapy approaches.

Indexed as

InsulinPancreasAnimalsCell- and Tissue-Based TherapyCell DifferentiationHumansStem CellsInsulincell replacement therapychemotherapy drugsdirect differentiationhuman pluripotent stem cellspancreatic insulin-producing beta cellsteratoma preventiontype 1 diabetes

Identifiers

PMID37315522
PMCPMC10277834
OpenAlexW4380629374

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.